Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 161 articles:
HTML format

Single Articles

    July 2021
  1. MCGARRY DJ, Armstrong G, Castino G, Mason S, et al
    MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours.
    Cancer Lett. 2021 Jul 24. pii: S0304-3835(21)00371.
    PubMed     Abstract available

  2. PENUGURTI V, Khumukcham SS, Padala C, Dwivedi A, et al
    HPIP protooncogene differentially regulates metabolic adaptation and cell fate in breast cancer cells under glucose stress via AMPK and RNF2 dependent pathways.
    Cancer Lett. 2021;518:243-255.
    PubMed     Abstract available

  3. GU J, Wang Y, Wang X, Zhou D, et al
    Retraction notice to "Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer" [Canc. Lett. 434 (2018) 1-10].
    Cancer Lett. 2021 Jul 14. pii: S0304-3835(21)00331.
    PubMed     Abstract available

  4. PETRI BJ, Piell KM, South Whitt GC, Wilt AE, et al
    HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
    Cancer Lett. 2021;518:152-168.
    PubMed     Abstract available

  5. XU X, Li N, Wang Y, Yu J, et al
    Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.
    Cancer Lett. 2021;519:150-160.
    PubMed     Abstract available

  6. MININI M, Senni A, He X, Proietti S, et al
    miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting.
    Cancer Lett. 2021 Jul 3. pii: S0304-3835(21)00326.
    PubMed     Abstract available

    June 2021
  7. SANG X, Li L, Rui C, Liu Y, et al
    Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
    Cancer Lett. 2021;518:82-93.
    PubMed     Abstract available

  8. REGUA AT, Arrigo A, Doheny D, Wong GL, et al
    Transgenic mouse models of breast cancer.
    Cancer Lett. 2021;516:73-83.
    PubMed     Abstract available

    May 2021
  9. DIMITRAKOPOULOS FI, Kottorou A, Tzezou A
    Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
    Cancer Lett. 2021 May 30. pii: S0304-3835(21)00254.
    PubMed     Abstract available

  10. WANG H, Shi Y, Chen CH, Wen Y, et al
    KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.
    Cancer Lett. 2021;515:49-62.
    PubMed     Abstract available

  11. LI X, Wang H, Yang X, Wang X, et al
    GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
    Cancer Lett. 2021 May 20. pii: S0304-3835(21)00194.
    PubMed     Abstract available

  12. PROVANCE OK, Geanes ES, Lui AJ, Roy A, et al
    Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
    Cancer Lett. 2021;514:12-29.
    PubMed     Abstract available

  13. LIGORIO F, Pellegrini I, Castagnoli L, Vingiani A, et al
    Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
    Cancer Lett. 2021 May 4. pii: S0304-3835(21)00189.
    PubMed     Abstract available

  14. WANG M, Dai M, Wang D, Tang T, et al
    The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway.
    Cancer Lett. 2021 May 2. pii: S0304-3835(21)00191.
    PubMed     Abstract available

    April 2021
  15. VENKATESH J, Wasson MD, Brown JM, Fernando W, et al
    LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
    Cancer Lett. 2021 Apr 10. pii: S0304-3835(21)00156.
    PubMed     Abstract available

  16. WANG CJ, Li D, Danielson JA, Zhang EH, et al
    Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Cancer Lett. 2021 Apr 1. pii: S0304-3835(21)00149.
    PubMed     Abstract available

    March 2021
  17. KAUL K, Misri S, Ramaswamy B, Ganju RK, et al
    Contribution of the tumor and obese microenvironment to triple negative breast cancer.
    Cancer Lett. 2021 Mar 30. pii: S0304-3835(21)00141.
    PubMed     Abstract available

    February 2021
  18. SONG D, He H, Sinha I, Hases L, et al
    Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    Cancer Lett. 2021 Feb 27. pii: S0304-3835(21)00092.
    PubMed     Abstract available

  19. HUANG M, Zhou Y, Duan D, Yang C, et al
    Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib.
    Cancer Lett. 2021 Feb 16. pii: S0304-3835(21)00074.
    PubMed     Abstract available

  20. ZHANG Y, Fan Y, Jing X, Zhao L, et al
    OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression.
    Cancer Lett. 2021 Feb 12. pii: S0304-3835(21)00068.
    PubMed     Abstract available

    January 2021
  21. BOURN JR, Ruiz-Torres SJ, Hunt BG, Benight NM, et al
    Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
    Cancer Lett. 2021 Jan 25. pii: S0304-3835(21)00035.
    PubMed     Abstract available

  22. CHENG R, Wang Z, Kong X, Qi L, et al
    Factors associated with chemotherapy benefit in breast cancer patients with midrange oncotype DX breast recurrence scores.
    Cancer Lett. 2021 Jan 21. pii: S0304-3835(21)00032.
    PubMed     Abstract available

  23. LI X, Chen M, Lu W, Tang J, et al
    Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
    Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
    PubMed     Abstract available

  24. YANG Y, Li S, Li B, Li Y, et al
    FBXL10 promotes ERRalpha protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERRalpha.
    Cancer Lett. 2021 Jan 12. pii: S0304-3835(21)00023.
    PubMed     Abstract available

    December 2020
  25. SHI Y, Zhang Y, Ran F, Liu J, et al
    Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Cancer Lett. 2020;495:53-65.
    PubMed     Abstract available

  26. ZHANG T, Wu B, Akakuru OU, Yao C, et al
    Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer.
    Cancer Lett. 2020;500:41-50.
    PubMed     Abstract available

  27. MAVINGIRE N, Campbell P, Wooten J, Aja J, et al
    Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes.
    Cancer Lett. 2020 Dec 9. pii: S0304-3835(20)30664.
    PubMed     Abstract available

  28. KIM SJ, Saeidi S, Cho NC, Kim SH, et al
    Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression: Implications for breast cancer progression.
    Cancer Lett. 2020 Dec 2. pii: S0304-3835(20)30645.
    PubMed     Abstract available

    November 2020
  29. WANG YY, Hung AC, Lo S, Yuan SF, et al
    Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
    Cancer Lett. 2020 Nov 2. pii: S0304-3835(20)30580.
    PubMed     Abstract available

  30. ZENG J, Li G, Xia Y, Wang F, et al
    miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.
    Cancer Lett. 2020;492:185-196.
    PubMed     Abstract available

    October 2020
  31. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    PubMed     Abstract available

  32. BAI X, Ni J, Beretov J, Graham P, et al
    Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Cancer Lett. 2020;497:100-111.
    PubMed     Abstract available

  33. ZHANG N, Sun P, Xu Y, Li H, et al
    The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERalpha to inhibit the growth of breast cancer induced by oestrogen.
    Cancer Lett. 2020 Oct 15. pii: S0304-3835(20)30545.
    PubMed     Abstract available

  34. DUTTA I, Dieters-Castator D, Papatzimas JW, Medina A, et al
    ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to gammadelta T cell immunotherapy.
    Cancer Lett. 2020 Oct 9. pii: S0304-3835(20)30535.
    PubMed     Abstract available

    September 2020
  35. OH JH, Lee JY, Kim KH, Kim CY, et al
    Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Cancer Lett. 2020;495:145-155.
    PubMed     Abstract available

  36. LI Y, Zhang H, Li Q, Zou P, et al
    CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
    Cancer Lett. 2020 Sep 14. pii: S0304-3835(20)30473.
    PubMed     Abstract available

  37. RONG Y, Huang LX, Yi KZ, Chen H, et al
    Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
    Cancer Lett. 2020 Sep 3. pii: S0304-3835(20)30455.
    PubMed     Abstract available

    August 2020
  38. MA L, Wang L, Nelson AT, Han C, et al
    27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
    Cancer Lett. 2020 Aug 27. pii: S0304-3835(20)30435.
    PubMed     Abstract available

  39. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals"[Cancer Lett. 386 (2017)12-23].
    Cancer Lett. 2020 Aug 25. pii: S0304-3835(20)30392.

  40. LOBO YA, Bonazza C, Batista FP, Castro RA, et al
    EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines.
    Cancer Lett. 2020 Aug 22. pii: S0304-3835(20)30431.
    PubMed     Abstract available

  41. ZHAO CC, Zhan MN, Liu WT, Jiao Y, et al
    Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
    Cancer Lett. 2020 Aug 20. pii: S0304-3835(20)30419.
    PubMed     Abstract available

  42. XIE Y, Hu Y, Zhou N, Yao C, et al
    CAR T-cell therapy for triple-negative breast cancer: Where we are.
    Cancer Lett. 2020 Aug 11. pii: S0304-3835(20)30400.
    PubMed     Abstract available

  43. TEOH ST, Ogrodzinski MP, Lunt SY
    UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30388.
    PubMed     Abstract available

  44. REN J, Wang Y, Ware T, Iaria J, et al
    Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30398.
    PubMed     Abstract available

    July 2020
  45. NIETO-JIMENEZ C, Galan-Moya EM, Corrales-Sanchez V, Del Mar Noblejas-Lopez M, et al
    Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Cancer Lett. 2020 Jul 28. pii: S0304-3835(20)30350.
    PubMed     Abstract available

  46. RONG D, Wang C, Zhang X, Wei Y, et al
    A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
    Cancer Lett. 2020 Jul 27. pii: S0304-3835(20)30355.
    PubMed     Abstract available

  47. HWANG HJ, Lee YR, Kang D, Lee HC, et al
    Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells.
    Cancer Lett. 2020 Jul 10. pii: S0304-3835(20)30349.
    PubMed     Abstract available

    June 2020
  48. HUANG B, Yip WK, Wei N, Luo KQ, et al
    Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
    Cancer Lett. 2020 Jun 22. pii: S0304-3835(20)30340.
    PubMed     Abstract available

  49. AGGARWAL V, Miranda O, Johnston PA, Sant S, et al
    Three dimensional engineered models to study hypoxia biology in breast cancer.
    Cancer Lett. 2020 Jun 19. pii: S0304-3835(20)30292.
    PubMed     Abstract available

  50. BABAK MV, Zalutsky MR, Balyasnikova IV
    Heterogeneity and vascular permeability of breast cancer brain metastases.
    Cancer Lett. 2020 Jun 16. pii: S0304-3835(20)30342.
    PubMed     Abstract available

  51. WANG B, Mao JH, Wang BY, Wang LX, et al
    Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-kappaB signaling pathway.
    Cancer Lett. 2020 Jun 9. pii: S0304-3835(20)30300.
    PubMed     Abstract available

    May 2020
  52. FERRER A, Roser CT, El-Far MH, Savanur VH, et al
    Hypoxia-mediated changes in bone marrow microenvironment in breast cancer dormancy.
    Cancer Lett. 2020 May 29. pii: S0304-3835(20)30288.
    PubMed     Abstract available

  53. BISHOP RT, Marino S, Carrasco G, Li B, et al
    Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
    Cancer Lett. 2020 May 28. pii: S0304-3835(20)30282.
    PubMed     Abstract available

  54. BARUA D, Gupta A, Gupta S
    Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges.
    Cancer Lett. 2020 May 21. pii: S0304-3835(20)30283.
    PubMed     Abstract available

  55. HE Z, Khatib AM, Creemers JWM
    Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
    Cancer Lett. 2020 May 7. pii: S0304-3835(20)30229.
    PubMed     Abstract available

    April 2020
  56. SZOOR A, Toth G, Zsebik B, Szabo V, et al
    Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
    Cancer Lett. 2020 Apr 11. pii: S0304-3835(20)30185.
    PubMed     Abstract available

  57. ULASOV I, Borovjagin A, Fares J, Yakushov S, et al
    MicroRNA 345 (miR345) regulates KISS1-E-cadherin functional interaction in breast cancer brain metastases.
    Cancer Lett. 2020;481:24-31.
    PubMed     Abstract available

    March 2020
  58. LIN CC, Lo MC, Moody R, Jiang H, et al
    Corrigendum to "Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer" [Canc. Lett. 438 (2018, Dec 1) 165-173].
    Cancer Lett. 2020 Mar 27. pii: S0304-3835(20)30021.

  59. ANG L, Guo L, Wang J, Huang J, et al
    Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
    Cancer Lett. 2020 Mar 18. pii: S0304-3835(20)30131.
    PubMed     Abstract available

  60. SHEN L, Kang L, Wang D, Xun J, et al
    Legumain-deficient macrophages promote senescence of tumor cells by sustaining JAK1/STAT1 activation.
    Cancer Lett. 2020;472:40-49.
    PubMed     Abstract available

    February 2020
  61. RIOS-LUCI C, Diaz-Rodriguez E, Gandullo-Sanchez L, Diaz-Gil L, et al
    Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
    Cancer Lett. 2020;470:161-169.
    PubMed     Abstract available

    January 2020
  62. DING J, Yao Y, Huang G, Wang X, et al
    Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30046.
    PubMed     Abstract available

  63. NAN X, Wang J, Cheng H, Yin Z, et al
    Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer Lett. 2020;469:195-206.
    PubMed     Abstract available

  64. WU J, Yan J, Fang P, Zhou HB, et al
    Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor alpha antagonism.
    Cancer Lett. 2020;469:78-88.
    PubMed     Abstract available

  65. GOH CY, Wyse C, Ho M, O'Beirne E, et al
    Exosomes in Triple Negative Breast Cancer: Garbage Disposals or Trojan Horses?
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30668.
    PubMed     Abstract available

  66. BAROK M, Le Joncour V, Martins A, Isola J, et al
    ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30659.
    PubMed     Abstract available

    December 2019
  67. SAND A, Piacsek M, Donohoe DL, Duffin AT, et al
    WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
    Cancer Lett. 2019;472:119-131.
    PubMed     Abstract available

  68. SI P, Shi J, Zhang P, Wang C, et al
    MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer.
    Cancer Lett. 2019 Dec 16. pii: S0304-3835(19)30625.
    PubMed     Abstract available

    November 2019
  69. PINA MJ, Girotti A, Serrano S, Munoz R, et al
    A Double Safety Lock Tumor-Specific Device for Suicide Gene Therapy in Breast Cancer.
    Cancer Lett. 2019 Nov 29. pii: S0304-3835(19)30586.
    PubMed     Abstract available

  70. PAN T, Zhou D, Shi Z, Qiu Y, et al
    Centromere Protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2.
    Cancer Lett. 2019 Nov 6. pii: S0304-3835(19)30558.
    PubMed     Abstract available

    October 2019
  71. KIM JE, Kim BG, Jang Y, Kang S, et al
    The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.
    Cancer Lett. 2019 Oct 28. pii: S0304-3835(19)30542.
    PubMed     Abstract available

    September 2019
  72. ZOU H, Chen H, Zhou Z, Wan Y, et al
    ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.
    Cancer Lett. 2019 Sep 26. pii: S0304-3835(19)30484.
    PubMed     Abstract available

    August 2019
  73. WANG S, Oh DY, Leventaki V, Drakos E, et al
    MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Cancer Lett. 2019;465:12-23.
    PubMed     Abstract available

  74. ANDRIEU GP, Shafran JS, Smith CL, Belkina AC, et al
    BET Protein Targeting Suppresses the PD-1/PD-L1 Pathway in Triple-Negative Breast Cancer and Elicits Anti-Tumor Immune Response.
    Cancer Lett. 2019 Aug 29. pii: S0304-3835(19)30450.
    PubMed     Abstract available

  75. QIU N, He YF, Zhang SM, Zhan YT, et al
    Cullin7 Enhances Resistance to Trastuzumab Therapy in Her2 Positive Breast Cancer via Degrading IRS-1 and Downregulating IGFBP-3 to Activate the PI3K/AKT Pathway.
    Cancer Lett. 2019 Aug 25. pii: S0304-3835(19)30439.
    PubMed     Abstract available

    July 2019
  76. KRISHNA BM, Jana S, Singhal J, Horne D, et al
    Notch Signaling in Breast Cancer: From Pathway Analysis to Therapy.
    Cancer Lett. 2019 Jul 18. pii: S0304-3835(19)30408.
    PubMed     Abstract available

    June 2019
  77. WANG HX, Gires O
    Tumor-derived extracellular vesicles in breast cancer: From bench to bedside.
    Cancer Lett. 2019;460:54-64.
    PubMed     Abstract available

    May 2019
  78. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed     Abstract available

  79. SANTIAGO-GOMEZ A, Kedward T, Simoes BM, Dragoni I, et al
    PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Cancer Lett. 2019 May 20. pii: S0304-3835(19)30309.
    PubMed     Abstract available

  80. SUN Q, Wang Y, Desgrosellier JS
    Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.
    Cancer Lett. 2019 May 9. pii: S0304-3835(19)30280.
    PubMed     Abstract available

  81. MO D, Jiang P, YiningYang, Mao X, et al
    A tRNA fragment, 5'-tiRNA(Val), suppresses the Wnt/beta-Catenin signaling pathway by targeting FZD3 in breast cancer.
    Cancer Lett. 2019 May 9. pii: S0304-3835(19)30283.
    PubMed     Abstract available

    April 2019
  82. DONG Q, Yang B, Han JG, Zhang MM, et al
    A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30268.
    PubMed     Abstract available

  83. WANG H, Yao F, Luo S, Ma K, et al
    A mutual activation loop between the Ca(2+)-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30264.
    PubMed     Abstract available

  84. SON D, Kim Y, Lim S, Kang HG, et al
    miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
    Cancer Lett. 2019;454:224-233.
    PubMed     Abstract available

  85. YANG Y, Zhu G, Dong B, Piao J, et al
    The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming.
    Cancer Lett. 2019;453:170-183.
    PubMed     Abstract available

    March 2019
  86. DIAZ-RODRIGUEZ E, Perez-Pena J, Rios-Luci C, Arribas J, et al
    TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30198.
    PubMed     Abstract available

  87. GUO L, Cheng X, Chen H, Chen C, et al
    Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis.
    Cancer Lett. 2019 Mar 24. pii: S0304-3835(19)30188.
    PubMed     Abstract available

  88. LIM JP, Nair S, Shyamasundar S, Chua PJ, et al
    Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression.
    Cancer Lett. 2019 Mar 21. pii: S0304-3835(19)30170.
    PubMed     Abstract available

  89. TANG X, Tu G, Yang G, Wang X, et al
    Autocrine TGF-beta1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation.
    Cancer Lett. 2019 Mar 6. pii: S0304-3835(19)30130.
    PubMed     Abstract available

    February 2019
  90. SOLINAS C, Marcoux D, Garaud S, Vitoria JR, et al
    BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
    Cancer Lett. 2019 Feb 21. pii: S0304-3835(19)30105.
    PubMed     Abstract available

  91. BISHOP RT, Marino S, de Ridder D, Allen RJ, et al
    Pharmacological inhibition of the IKKepsilon/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
    Cancer Lett. 2019 Feb 18. pii: S0304-3835(19)30110.
    PubMed     Abstract available

  92. AHMED K, Koval A, Xu J, Bodmer A, et al
    Towards the first targeted therapy for triple-negative breast cancer: repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30090.
    PubMed     Abstract available

  93. MARQUEZ-GARBAN DC, Gorrin-Rivas M, Chen HW, Sterling C Jr, et al
    Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30081.
    PubMed     Abstract available

  94. MA F, Liu X, Zhou S, Li W, et al
    Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30080.
    PubMed     Abstract available

  95. HE Q, Xue S, Tan Y, Zhang L, et al
    Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
    Cancer Lett. 2019 Feb 8. pii: S0304-3835(19)30070.
    PubMed     Abstract available

    January 2019
  96. FU S, Chen X, Lo HW, Lin J, et al
    Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Cancer Lett. 2019 Jan 29. pii: S0304-3835(19)30046.
    PubMed     Abstract available

  97. CHO TM, Kim JY, Kim YJ, Sung D, et al
    C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cancer Lett. 2019 Jan 28. pii: S0304-3835(19)30049.
    PubMed     Abstract available

  98. ZHANG K, Hong R, Kaping L, Xu F, et al
    CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
    Cancer Lett. 2019 Jan 21. pii: S0304-3835(19)30017.
    PubMed     Abstract available

  99. YOON HJ, Kim DH, Kim SJ, Jang JH, et al
    Src-mediated phosphorylation, ubiquitination and degradation of Caveolin-1 promotes breast cancer cell stemness.
    Cancer Lett. 2019 Jan 20. pii: S0304-3835(19)30033.
    PubMed     Abstract available

  100. VELLANKI SH, Cruz RGB, Jahns H, Hudson L, et al
    Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth.
    Cancer Lett. 2019;440-441:23-34.
    PubMed     Abstract available

    December 2018
  101. TU M, Lu C, Lv N, Wei J, et al
    Corrigendum to 'Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2' [Cancer Lett. 2016 Dec 28; 383 (2):272-281].
    Cancer Lett. 2018 Dec 26. pii: S0304-3835(18)30717.

  102. ZHANG X, Gao D, Fang K, Guo Z, et al
    Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
    Cancer Lett. 2018 Dec 21. pii: S0304-3835(18)30723.
    PubMed     Abstract available

  103. YUAN G, Lian Z, Liu Q, Lin X, et al
    Phosphatidyl Inositol 3-Kinase (PI3K)-mTOR Inhibitor PKI-402 Inhibits Breast Cancer Induced Osteolysis.
    Cancer Lett. 2018 Dec 9. pii: S0304-3835(18)30704.
    PubMed     Abstract available

    November 2018
  104. ZOU H, Sevigny MB, Liu S, Madden DT, et al
    Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30688.
    PubMed     Abstract available

  105. THAKUR V, Zhang K, Savadelis A, Zmina P, et al
    The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA Damage Response that impacts chemo- and radiotherapy responses of breast cancer.
    Cancer Lett. 2018 Nov 28. pii: S0304-3835(18)30697.
    PubMed     Abstract available

  106. YU L, Wang L, Mao C, Duraki D, et al
    Estrogen-Independent Myc Overexpression Confers Endocrine Therapy Resistance on Breast Cancer Cells Expressing ERalphaY537S and ERalphaD538G Mutations.
    Cancer Lett. 2018 Nov 9. pii: S0304-3835(18)30662.
    PubMed     Abstract available

  107. WANG X, Qi Y, Kong X, Zhai J, et al
    Recent Advances in the Research of Immunotherapy for Triple-Negative Breast Cancer.
    Cancer Lett. 2018 Nov 9. pii: S0304-3835(18)30664.
    PubMed     Abstract available

    October 2018
  108. GUPTA P, Gupta N, Fofaria NM, Ranjan A, et al
    HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells.
    Cancer Lett. 2018;442:68-81.
    PubMed     Abstract available

  109. SUN HF, Yang XL, Zhao Y, Tian Q, et al
    Loss of TMEM126A promotes extracellular matrix remodeling, epithelial-to-mesenchymal transition, and breast cancer metastasis by regulating mitochondrial retrograde signaling.
    Cancer Lett. 2018;440-441:189-201.
    PubMed     Abstract available

  110. WEN S, Hou Y, Fu L, Xi L, et al
    Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta3-p38 MAPK signalling.
    Cancer Lett. 2018 Oct 26. pii: S0304-3835(18)30629.
    PubMed     Abstract available

  111. XIAO YS, Zeng, Liang YK, Wu Y, et al
    Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
    Cancer Lett. 2018 Oct 15. pii: S0304-3835(18)30608.
    PubMed     Abstract available

  112. DING J, Wang X, Zhang Y, Sang X, et al
    Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kalpha inhibition through the transcriptional regulation of ERalpha.
    Cancer Lett. 2018 Oct 10. pii: S0304-3835(18)30605.
    PubMed     Abstract available

    September 2018
  113. ZHANG C, Zhang M, Song S
    Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30576.
    PubMed     Abstract available

  114. LIN CC, Lo MC, Moody R, Jiang H, et al
    Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30577.
    PubMed     Abstract available

    August 2018
  115. BARONE I, Vircillo V, Giordano C, Gelsomino L, et al
    Activation of Farnesoid X Receptor Impairs The Tumor-Promoting Function of Breast Cancer-Associated Fibroblasts.
    Cancer Lett. 2018 Aug 31. pii: S0304-3835(18)30544.
    PubMed     Abstract available

  116. WU Q, Chen D, Luo Q, Yang Q, et al
    Extracellular matrix protein 1 recruits moesin to facilitate invadopodia formation and breast cancer metastasis.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30540.
    PubMed     Abstract available

  117. ZHANG H, Zhang Y, Chen C, Zhu X, et al
    A double-negative feedback loop between DEAD-box protein DDX21 and Snail regulates epithelial-mesenchymal transition and metastasis in breast cancer.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30539.
    PubMed     Abstract available

  118. LOPES R, Korkmaz G, Revilla SA, van Vliet R, et al
    CUEDC1 is a primary target of ERalpha essential for the growth of breast cancer cells.
    Cancer Lett. 2018;436:87-95.
    PubMed     Abstract available

    July 2018
  119. DYCZYNSKI M, Yu Y, Otrocka M, Parpal S, et al
    Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
    Cancer Lett. 2018 Jul 25. pii: S0304-3835(18)30486.
    PubMed     Abstract available

  120. NIKAS I, Ryu HS, Theocharis S
    Viewing the Eph receptors with a focus on breast cancer heterogeneity.
    Cancer Lett. 2018;434:160-171.
    PubMed     Abstract available

  121. FAN TC, Yeo HL, Hsu HM, Yu JC, et al
    Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
    Cancer Lett. 2018 Jul 21. pii: S0304-3835(18)30484.
    PubMed     Abstract available

  122. CHEN X, Liu P, Wang Q, Li Y, et al
    DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Cancer Lett. 2018 Jul 11. pii: S0304-3835(18)30470.
    PubMed     Abstract available

  123. LIU XL, Xu YC, Wang YX, Chen Y, et al
    Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kalpha-selective inhibitor CYH33 in breast cancer.
    Cancer Lett. 2018 Jul 9. pii: S0304-3835(18)30469.
    PubMed     Abstract available

    June 2018
  124. GU J, Wang Y, Wang X, Zhou D, et al
    Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer.
    Cancer Lett. 2018 Jun 30. pii: S0304-3835(18)30447.
    PubMed     Abstract available

  125. XIAO Y, Li Y, Tao H, Humphries B, et al
    Integrin alpha5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Cancer Lett. 2018 Jun 29. pii: S0304-3835(18)30445.
    PubMed     Abstract available

  126. SALINAS-VERA YM, Marchat LA, Garcia-Vazquez R, Gonzalez de la Rosa CH, et al
    Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells.
    Cancer Lett. 2018;432:17-27.
    PubMed     Abstract available

  127. SAUVAGE F, Fattal E, Al-Shaer W, Denis S, et al
    Antitumor activity of nanoliposomes encapsulating the novobiocin analogue 6BrCaQ in a triple-negative breast cancer model in mice.
    Cancer Lett. 2018 Jun 5. pii: S0304-3835(18)30397.
    PubMed     Abstract available

    May 2018
  128. WU J, Jiang Z, Chen C, Hu Q, et al
    CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis.
    Cancer Lett. 2018;430:179-192.
    PubMed     Abstract available

  129. SOHN EJ, Jung DB, Lee H, Han I, et al
    Corrigendum to "CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells" [Cancer Lett 412 (2018 Jan 1) 88-98].
    Cancer Lett. 2018 May 19. pii: S0304-3835(18)30321.

  130. LI Y, Huang J, Zeng B, Yang D, et al
    PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation.
    Cancer Lett. 2018 May 16. pii: S0304-3835(18)30343.
    PubMed     Abstract available

  131. YAN M, Wang Y, Wong CW, Mei-Yu Or P, et al
    PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model.
    Cancer Lett. 2018 May 14. pii: S0304-3835(18)30337.
    PubMed     Abstract available

  132. LIU Y, Geng YH, Yang H, Yang H, et al
    Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts.
    Cancer Lett. 2018 May 4. pii: S0304-3835(18)30318.
    PubMed     Abstract available

    April 2018
  133. GELSOMINO L, Panza S, Giordano C, Barone I, et al
    Mutations in the Estrogen Receptor Alpha Hormone Binding Domain Promote Stem Cell Phenotype through Notch Activation in Breast Cancer Cell Lines.
    Cancer Lett. 2018 Apr 24. pii: S0304-3835(18)30290.
    PubMed     Abstract available

  134. OJO D, Lin X, Wu Y, Cockburn J, et al
    Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Cancer Lett. 2018;426:4-13.
    PubMed     Abstract available

    March 2018
  135. ZANOTTO-FILHO A, Rajamanickam S, Loranc E, Masamsetti P, et al
    Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.
    Cancer Lett. 2018 Mar 30. pii: S0304-3835(18)30240.
    PubMed     Abstract available

  136. LAWSON JS, Salmons B, Gunzburg WH
    Commentary regarding Gannon et al. "Viral infections and breast cancer - A current perspective".
    Cancer Lett. 2018;424:117-118.

  137. LI D, Wang H, Ding Y, Zhang Z, et al
    Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis.
    Cancer Lett. 2018;424:97-108.
    PubMed     Abstract available

  138. SUH J, Kim DH, Kim EH, Park SA, et al
    15-Deoxy-Delta(12,14)-prostaglandin J2 activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN at cysteine 136.
    Cancer Lett. 2018 Mar 14. pii: S0304-3835(18)30207.
    PubMed     Abstract available

  139. FERNANDEZ-NOGUEIRA P, Noguera-Castells A, Fuster G, Recalde-Percaz L, et al
    Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.
    Cancer Lett. 2018 Mar 13. pii: S0304-3835(18)30205.
    PubMed     Abstract available

    February 2018
  140. HU Y, Yague E, Zhao J, Wang L, et al
    Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
    Cancer Lett. 2018 Feb 26. pii: S0304-3835(18)30177.
    PubMed     Abstract available

  141. GANNON OM, Antonsson A, Bennett IC, Saunders NA, et al
    Viral infections and breast cancer - A current perspective.
    Cancer Lett. 2018 Feb 2. pii: S0304-3835(18)30117.
    PubMed     Abstract available

    January 2018
  142. LYU H, Wang S, Huang J, Wang B, et al
    Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Cancer Lett. 2018 Jan 30. pii: S0304-3835(18)30098.
    PubMed     Abstract available

  143. WANG QS, He R, Yang F, Kang LJ, et al
    FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway.
    Cancer Lett. 2018 Jan 30. pii: S0304-3835(18)30102.
    PubMed     Abstract available

  144. JIN Y, Hu W, Liu T, Rana U, et al
    Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
    Cancer Lett. 2018 Jan 23. pii: S0304-3835(18)30087.
    PubMed     Abstract available

  145. GUO W, Hao B, Luo N, Ruan D, et al
    Early re-staging and molecular subtype shift surveillance of locally recurrent or metastatic breast cancer: A new PET/CT integrated precise algorithm.
    Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30041.
    PubMed     Abstract available

  146. ZIELINSKA HA, Holly JMP, Bahl A, Perks CM, et al
    Inhibition of FASN and ERalpha signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30050.
    PubMed     Abstract available

  147. ZHOU KX, Xie LH, P X, Guo QM, et al
    CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
    Cancer Lett. 2018 Jan 6. pii: S0304-3835(18)30031.
    PubMed     Abstract available

    December 2017
  148. PLATONOV ME, Borovjagin AV, Kaverina N, Xiao T, et al
    KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro.
    Cancer Lett. 2017 Dec 18. pii: S0304-3835(17)30796.
    PubMed     Abstract available

  149. KIM HY, Ha Thi HT, Hong S
    IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Cancer Lett. 2017;415:30-39.
    PubMed     Abstract available

    November 2017
  150. CAI X, Wang X, Cao C, Gao Y, et al
    HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
    Cancer Lett. 2017 Nov 21. pii: S0304-3835(17)30740.
    PubMed     Abstract available

  151. KIM YJ, Sung D, Oh E, Cho Y, et al
    Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
    Cancer Lett. 2017;412:118-130.
    PubMed     Abstract available

    October 2017
  152. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals" [Cancer Lett. 386 (2017) 12-23].
    Cancer Lett. 2017 Oct 30. pii: S0304-3835(17)30662.

  153. BAI XY, Li S, Wang M, Li X, et al
    Kruppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
    Cancer Lett. 2017;412:224-235.
    PubMed     Abstract available

  154. SYNNOTT NC, Bauer MR, Madden S, Murray A, et al
    Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30622.
    PubMed     Abstract available

  155. WILMANSKI T, Zhou X, Zheng W, Shinde A, et al
    Inhibition of Pyruvate Carboxylase by 1alpha,25-Dihydroxyvitamin D Promotes Oxidative Stress in Early Breast Cancer Progression.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30606.
    PubMed     Abstract available

  156. SOHN EJ, Jung DB, Lee H, Han I, et al
    CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30621.
    PubMed     Abstract available

  157. FIGUEIRA MI, Cardoso HJ, Correia S, Maia CJ, et al
    The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?
    Cancer Lett. 2017;405:10-21.
    PubMed     Abstract available

    September 2017
  158. MARINO S, Bishop RT, Logan JG, Mollat P, et al
    Pharmacological evidence for the bone-autonomous contribution of the NFkappaB/beta-catenin axis to breast cancer related osteolysis.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30587.
    PubMed     Abstract available

  159. OLADAPO HO, Tarpley M, Sauer SJ, Addo KA, et al
    Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30586.
    PubMed     Abstract available

  160. XU H, Lin F, Wang Z, Yang L, et al
    CXCR2 Promotes Breast Cancer Metastasis and Chemoresistance via suppression of AKT1 and activation of COX2.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30583.
    PubMed     Abstract available

  161. WANG S, Zhou R, Sun F, Li R, et al
    The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30551.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.